GlaxoSmithKline plc announced a regulatory submission to the US Food and Drug Administration (US FDA) for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world. GSK intends to submit a regulatory application in the European Union in early 2013.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,495 GBX | -0.40% |
|
-0.56% | +3.19% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.19% | 79.3B | |
+61.53% | 848B | |
+33.75% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+11.74% | 234B | |
+15.11% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GlaxoSmithKline plc Announces Submission of Albiglutide BLA to the US FDA for the Treatment of Type 2 Diabetes